Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s141. https://doi.org/10.25251/skin.7.supp.141